New Era in Cancer Treatment at ESMO 2026 Congress

At the ESMO 2026 congress held in Madrid from October 23-27, 2026, by the European Society for Medical Oncology (ESMO), data from 12 major clinical studies expected to be groundbreaking in cancer treatment are being presented.

At the center of the congress agenda are personalized mRNA therapies and innovative drugs that direct the immune system directly to cancer cells. Notably, the DeLLphi-305 study, focusing on small cell lung cancer treatment, and the MOIO study, aiming to reduce treatment frequency in immunotherapy, are drawing attention in terms of efficacy and patient quality of life.

Experts state that the effects of the newly presented treatment methods on patients' lifespan should be evaluated holistically along with side effects, treatment access criteria, and overall quality of life data.